Table 5. Effects of the disease incidence rate and disease severity index of gummosis for different treatments in the field trial.
| Treatment | Cell suspension | Lipopeptide liquor | Carbendazol | Water |
|---|---|---|---|---|
| 2014 | ||||
| IGR (%) | 80.0b | 90.0ab | 100.0a | 100.0a |
| DSI (%) | 27.5c | 32.5c | 57.5b | 85.0a |
| 2015 | ||||
| IGR (%) | 60.0c | 80.0b | 100.0a | 100.0a |
| DSI (%) | 22.5c | 30.0c | 60.0b | 80.0a |
For the data for treatments that were summarized from the same trees in 2014 and 2015, each treatment had 10 replications. The suspension concentration was 2×106 cfu/mL and the carbendazol concentration was 200 μg/mL. Distilled water was used as a control. The different letters (a, b and c) listed after each number represent significant difference between treatments and control (P<0.05) by Duncan’s test.